Clinical characteristics of the women at baseline and the characteristics at follow-up
| . | No-thrombophilia . | Thrombophilia . | P . |
|---|---|---|---|
| N | 796 | 279 | |
| Age, y | 30 (5) [17-44] | 29 (4) [18-44] | .19 |
| >35 y, n (%) | 43 (5.4) | 12 (4.3) | .47 |
| Body mass index, kg/m2 (%) | 25.6 (4.5) | 25.9 (4.2) | .19 |
| [15.3-36.1] | [13.5-34.1] | ||
| >30 kg/m2 (%) | 78 (9.8) | 29 (10.4) | .78 |
| <18.5 kg/m2 (%) | 12 (1.5) | 3 (1.1) | .82 |
| Ethnicity (%) | .89 | ||
| Whites | 753 (94.6) | 264 (94.6) | |
| Europeans | 647 (81.3) | 227 (81.4) | |
| North Africans | 106 (13.3) | 37 (13.2) | |
| Black Africans | 36 (4.5) | 12 (4.3) | |
| Asians | 7 (0.9) | 3 (1.1) | |
| PL subtypes (%) | |||
| Embryonic PL <10 WG | 483 (60.7) | 93 (33.3) | <.0001 |
| Fetal PL >10 WG | 313 (39.3) | 186 (66.6) | |
| Primary PL | 549 (68.9) | 185 (66.3) | .41 |
| Secondary PL | 247 (31.1) | 94 (33.7) | |
| Inflammatory disease (%) | 7 (0.9) | 4 (1.4) | .66 |
| Current tobacco users (%) | 83 (10.4) | 30 (10.8) | .88 |
| Hypertension (%) | 19 (2.4) | 8 (2.9) | .83 |
| Positive history in a first-degree relative (%) | |||
| Venous thromboembolism | 15 (1.9) | 29 (10.4) | <.0001 |
| Atherothrombosis | 96 (12.1) | 46 (16.5) | .062 |
| Recurrent abortions | 49 (6.2) | 18 (6.5) | .86 |
| Fetal death | 33 (4.1) | 26 (9.3) | .0011 |
| Hyperlipidemia (%) | |||
| hypercholesterolemia | 42 (5.3) | 13 (4.7) | .69 |
| hypertriglyceridemia | 34 (4.3) | 11 (3.9) | .81 |
| Interval between the inclusion and the new pregnancy attempt | |||
| Duration, days (%) | 156 (29) | 148 (31) | .43 |
| [95-386] | [98-369] |
| . | No-thrombophilia . | Thrombophilia . | P . |
|---|---|---|---|
| N | 796 | 279 | |
| Age, y | 30 (5) [17-44] | 29 (4) [18-44] | .19 |
| >35 y, n (%) | 43 (5.4) | 12 (4.3) | .47 |
| Body mass index, kg/m2 (%) | 25.6 (4.5) | 25.9 (4.2) | .19 |
| [15.3-36.1] | [13.5-34.1] | ||
| >30 kg/m2 (%) | 78 (9.8) | 29 (10.4) | .78 |
| <18.5 kg/m2 (%) | 12 (1.5) | 3 (1.1) | .82 |
| Ethnicity (%) | .89 | ||
| Whites | 753 (94.6) | 264 (94.6) | |
| Europeans | 647 (81.3) | 227 (81.4) | |
| North Africans | 106 (13.3) | 37 (13.2) | |
| Black Africans | 36 (4.5) | 12 (4.3) | |
| Asians | 7 (0.9) | 3 (1.1) | |
| PL subtypes (%) | |||
| Embryonic PL <10 WG | 483 (60.7) | 93 (33.3) | <.0001 |
| Fetal PL >10 WG | 313 (39.3) | 186 (66.6) | |
| Primary PL | 549 (68.9) | 185 (66.3) | .41 |
| Secondary PL | 247 (31.1) | 94 (33.7) | |
| Inflammatory disease (%) | 7 (0.9) | 4 (1.4) | .66 |
| Current tobacco users (%) | 83 (10.4) | 30 (10.8) | .88 |
| Hypertension (%) | 19 (2.4) | 8 (2.9) | .83 |
| Positive history in a first-degree relative (%) | |||
| Venous thromboembolism | 15 (1.9) | 29 (10.4) | <.0001 |
| Atherothrombosis | 96 (12.1) | 46 (16.5) | .062 |
| Recurrent abortions | 49 (6.2) | 18 (6.5) | .86 |
| Fetal death | 33 (4.1) | 26 (9.3) | .0011 |
| Hyperlipidemia (%) | |||
| hypercholesterolemia | 42 (5.3) | 13 (4.7) | .69 |
| hypertriglyceridemia | 34 (4.3) | 11 (3.9) | .81 |
| Interval between the inclusion and the new pregnancy attempt | |||
| Duration, days (%) | 156 (29) | 148 (31) | .43 |
| [95-386] | [98-369] |
No-thrombophilia indicates women with a negative thrombophilia screening result. Thrombophilia indicates women testing positive for a F5 rs6025 or F2 rs1799963 polymorphism. Quantitative data are given as median (interquartile range) [range] values, qualitative data as number (percentage) values.
PL, pregnancy loss.